We are broadly interested in how energy is regulated on a systems level during infection. Our current projects are focused on understanding the role that adipose tissue plays in the response to influenza and SARS-CoV2.
The Reinecker laboratory unravels and targets molecular mechanisms of key human genetic variants that cause chronic inflammatory diseases and cancer by creating novel genetic mouse and human organotypic model systems.
We investigate the mechanism of neurotransmitter release using a variety of biophysical approaches, including NMR spectroscopy, X-ray crystallography, cryo-EM, molecular dynamics simulations and liposome fusion assays.
The significance of our research is to show effective anti-Aβ42 antibody production in large animals and safety of DNA Aβ42 immunotherapy in these models to proceed with vaccination in patients at risk for Alzheimer’s disease.